Patent classifications
C12N2760/18134
IMPROVED HVT-VECTORED ND-IBD VACCINE
The present invention regards a new and Improved HVT-vectored ND-IBD vaccine, comprising a recombinant HVT comprising the VP2 gene from IBDV and the F gene from NDV to a target animal. The recombinant HVT can be used in a vaccine for poultry, which displayed good viral vector replication, effective expression of the NDV F—and IBDV VP2 genes, improved immunoprotection against ND and IBD, and improved genetic stability over prior art constructs.
tFIBER PROTEIN FRAGMENT OF AVIAN EGG DROP SYNDROME VIRUS AND VACCINE COMPOSITION PREPARED THEREOF, PREPARATION METHOD AND USE
The present disclosure provides a tFiber protein fragment of avian egg drop syndrome virus, wherein the gene that encoded the tFiber protein fragment of avian egg drop syndrome virus has a nucleotide sequence shown in SEQ ID NO. 2 or a degenerate sequence thereof, and a vaccine composition prepared from the protein fragment. The fragment has good immunogenicity and is capable of preparing combined vaccine with various antigens, producing complete protection to the chickens and ducks.
RECOMBINANT CHICKEN INTERLEUKIN-1 BETA PROTEIN FOR PRODUCING ANTIBODY EARLY AND RETAINING FOR A LONGER PERIOD OF TIME AND APPLICATION THEREOF
The present invention provides a recombinant chicken interleukin-1β protein for producing antibody early and retaining for a longer period of time, which has a sequence of SEQ ID NO:2 or SEQ ID NO:3. The recombinant chicken interleukin-1β protein is created by using point mutation in a genetic engineering method; it can significantly improve the original vaccine efficacy to enhance antibody responses, produce antibody one week earlier and extend the protective effect until chickens sold off. Therefore, the recombinant chicken interleukin-1β protein of the present invention can produce significant higher antibody responses than the with-type chicken interleukin-1β protein, it helps to develop avian interleikin-1β vaccine adjuvant and uses in medical application and livestock production.
Recombinant gallid herpesvirus 3 (MDV serotype 2) vectors expressing antigens of avian pathogens and uses thereof
The present invention provides recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain and express antigens of avian pathogens, recombinant Gallid herpesvirus 3 (MDV-2) vectors that contain a mutated gC gene, compositions comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors, polyvalent vaccines comprising the recombinant Gallid herpesvirus 3 (MDV-2) vectors and one or more wild type viruses or recombinant vectors. The present invention further provides methods of vaccination against a variety of avian pathogens and method of producing the recombinant Gallid herpesvirus 3 (MDV-2) vectors.
Acceleration of vector virus induced immune response in avians
The addition of an oligodeoxynucleotide that is an avian TLR21 agonist, to an avian Herpesvirus vector vaccine, provides an acceleration of the immune response against the antigen that is expressed and delivered by the Herpesvirus vector.
RECOMBINANT AVIAN HERPES VIRUSES CONTAINING MULTIPLE FOREIGN GENES
The present invention relates to recombinant avian herpes viruses containing multiple genes inserted into separate intergenic regions, their manufacture, compositions comprising the same, and the uses thereof.
METHODS FOR IMMUNIZING PRE-IMMUNE SUBJECTS AGAINST RESPIRATORY SYNCYTIAL VIRUS (RSV)
The invention provides methods for using virus-like particle (VLP) vaccines containing a stabilized pre-fusion respiratory syncytial virus (RSV) F protein to stimulate RSV neutralizing antibodies in pre-immune subjects. In one embodiment, the invention provides a method for immunizing a mammalian subject in need of immunizing against Respiratory Syncytial virus (RSV) infection, comprising, a) providing i) a pre-immune mammalian subject containing RSV neutralizing antibodies, ii) a first composition comprising recombinant chimeric Newcastle disease virus-like particles (ND VLPs), that contain a chimeric protein comprising, in N operable combination, 1) stabilized pre-fusion RSV F protein ectodomain, 2) transmembrane (TM) domain of NDV F protein, and 3) cytoplasmic (CT) domain of NDV F protein, and b) administering an immunologically effective amount of the first composition to the pre-immune subject to produce an immunized subject that comprises an increase in the level of the RSV neutralizing antibodies compared to the level of RSV neutralizing antibodies in the pre-immune subject. In one embodiment, the level of the RSV neutralizing antibodies in the pre-immune subject does not prevent RSV infection of the pre-immune subject.
MULTIVALENT RECOMBINANT AVIAN HERPES VIRUSES AND VACCINES FOR IMMUNIZING AVIAN SPECIES
The present invention relates to a recombinant avian herpes virus, which comprises at least two recombinant nucleotide sequences, each recombinant nucleotide sequence encoding a distinct antigenic peptide, wherein the at least two recombinant nucleotide sequences are inserted into distinct non-coding regions of the viral genome chosen among the region located between UL44 and UL45, the region located between UL45 and UL46, the region located between US10 and SORF3, and the region located between SORF3 and US2.
VACCINE AGAINST INFECTIOUS BRONCHITIS
Poultry vaccines against infectious bronchitis and Turkey Rhinotracheitis are provided. The vaccines are adjuvanted with oil emulsion containing an immunostimulatory oligonucleotide. The methods of using the vaccines are also provided.
Production of flu vaccine in <i>Myceliophthora thermophila</i>
Recombinant expression of influenza virus surface proteins in the fungus Myceliophthora thermophila strain C1 is provided. The recombinant proteins are for use in influenza vaccine compositions.